Lv5
1240 积分 2021-06-08 加入
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
6天前
已完结
BCMA-CAR T-cells in a patient with relapsing idiopathic inflammatory myositis after CD19-CAR T-cells
7天前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
8天前
已完结
Hexachlorophene-induced brain edema in rat observed by proton magnetic resonance
8天前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
17天前
已完结
CD8αα and CD8αβ: truly different?
17天前
已完结
Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1
17天前
已完结
A PD-L1/CD3 BISPECIFIC ANTIBODY ENHANCES THE ANTI-TUMOR EFFECTS OF REGORAFENIB AGAINST COLON CANCER
17天前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
19天前
已完结
From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials
19天前
已完结
皖公网安备34019202002308
